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The aim of this study was to compare the efficacy and safety of salmeterol vs theophylline in asthma management 
using meta-analysis of clinical trials. Nine clinical studies, containing a total of 1330 patients, met meta-analysis 
inclusion criteria: randomized, controlled study, minimum 2-week treatment duration with either salmeterol or 
theophylline. The main outcome measurements were morning and evening peak expiratory flow rate (PEFR), 
morning and evening symptom scores, use of salbutamol as rescue medication, and withdrawal from treatment for 
any cause. During the second week of treatment, salmeterol patients had a 10 1 min - ’ greater increase in mean 
morning PEFR from baseline than theophylline patients (P<O.OOl). Similarly, in the second week, the increase in 
mean evening PEFR from baseline observed with salmeterol was significantly greater (P<O.Ol) than that observed 
with theophylline. Salmeterol also produced a significantly greater increase in mean morning and evening PEFR 
than theophylline at weeks 3 and 4. Patients receiving salmeterol were free from daytime symptoms for a mean of 
51% of days in the second week compared to 39% for theophylline patients (P<O.OOl). Salmeterol patients 
experienced a mean of 63% symptom-free nights compared to 52% for theophylline patients (P<O.OOl). Rescue 
medication with salbutamol was not required on 49% of days for salmeterol patients and 34% of days for 
theophylline patients. All results were maintained in the third and fourth weeks of treatment. Withdrawal and 
incidence of adverse events leading to withdrawal were significantly less frequent in patients receiving salmeterol 
(P<O.OOl). Thus, this meta-analysis suggests that salmeterol has a superior safety and efficacy profile to theophylline 
in the management of symptoms of chronic asthma. 
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Introduction 
The long-acting &-adrenoceptor agonist salmeterol, admin- 
istered at a dose of 5Opg twice daily from a metered-dose 
inhaler or in powder form, has been shown to be an 
effective long-acting bronchodilator for the management of 
asthma symptoms (1,2). Salmeterol has been shown to 
significantly increase morning and evening peak flow, 
reduce nocturnal variations in peak flow, alleviate the 
symptoms of asthma and reduce the requirement for 
additional bronchodilator therapy (3,4). Salmeterol has 
been shown to have similar clinical efficacy (peak effect) to 
other &adrenoceptor agonists, such as salbutamol and 
terbutaline (1,5), with a slower onset and a longer duration 
of action. 
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Theophylline, a methylxanthine, has now been available 
for over 60 years and is seen to have a role and position in 
asthma management guidelines (6,7). However, there are 
disadvantages associated with the drug; theophylline has a 
narrow therapeutic index and the dose must be carefully 
titrated with routine blood monitoring to maintain blood 
levels within the therapeutic range of lo-20 pg ml ~ ’ and to 
avoid toxicity (8,9). 
The effects of salmeterol and theophylline had 
been reported in a variety of studies and clinical reports, 
and in an attempt to further examine and compare 
the roles of these two drugs in the management of 
asthma, a meta-analytical approach was used (10,ll). 
The present authors’ undertook a meta-analysis of the 
efficacy and safety of inhaled salmeterol, 5Opg twice 
daily, vs twice daily oral theophylline, using available 
GlaxoWellcome studies that achieved the criteria for 
inclusion. 
This data was presented in a preliminary form at 
the European Respiratory Society, Barcelona, 16-20 
September 1995 (12). 
0 1998 W. B. SAUNDERS COMPANY LTD 
SALMETEROL VSTHEOPHYLLINE 257 
Methods 
IDENTIFICATION OF RELEVANT CLINICAL 
STUDIES 
All Glaxo Wellcome studies that were known to the authors 
and had data available as of November 1994 were eligible 
for inclusion in the analysis. Requests for data were made 
to the sponsoring country of each study. Studies were 
included in the meta-analysis if they were randomized, 
controlled and were of at least 2 weeks’ continuous 
treatment duration. 
ASSESSMENT OF TREATMENT 
All patients gave their written informed consent before 
entry to the appropriate study, and Ethics Committee 
approval was obtained from the appropriate local com- 
mittee. All studies were conducted in accordance with the 
Declaration of Helsinki 1964, revised in Tokyo 1975, 
Venice 1983 and Hong Kong 1989. 
At the initial visit, patients were instructed in the correct 
use of the mini-Wright peak flow meter and were shown 
how to complete their daily record cards. Patients measured 
and recorded their peak expiratory flow rate (PEFR) in the 
morning and evening before medication, and their use of 
salbutamol as rescue medication. Patients also recorded 
their asthma symptom score during the day and night. 
Lung function measurement [forced expiratory volume in 
1 s (FEV,), PEFR and forced vital capacity] were measured 
at clinic visits as described for each study. Measurements 
were performed for each patient at the same time of day 
during each clinic visit, and at least 4 h after the last 
salbutamol inhalation. Adverse events were also recorded 
during each study. 
ASTHMA EXACERBATIONS 
Treatment of acute exacerbations of asthma was at the 
discretion of the individual physician. Patients continued to 
complete their diary cards and were not withdrawn from 
treatment unless the physician considered it necessary. Data 
generated following acute exacerbations were not used in 
the assessment of efficacy. 
STATISTICAL METHODS 
A simple meta-analysis could be used because all of the 
studies included were carried out by GlaxoWellcome and 
the actual patient data was available. Hence, the need for 
complex statistical methodology, as is the situation for 
meta-analysis of studies where all the patient information is 
not available, was not necessary. 
Mean morning PEFR and mean evening PEFR were 
analysed parametrically using a fixed effects analysis of 
covariance model. Terms for study centre, sex and treat- 
ment were included in the model, together with covariates 
for age and baseline value. Two-sided P values and 95% 
confidence intervals were calculated for the treatment 
difference from this model using P<O.O5. 
Five of the nine studies involved a titration period for 
theophylline. Thus, the influence of titration compared with 
non-titration was explored by including titration as a main 
effect and considering interaction terms containing it. 
Data collected on symptoms and bronchodilator use was 
non-parametrically analysed using a Wilcoxon rank sum 
test stratified by sex and study. Symptom score scales 
differed between studies but there was a common code for 
‘no symptoms’ in all of the nine studies. This is used to 
summarize data on each patient; by expressing the data 
as the percent of symptom-free days/nights, it was then 
possible to combine the data across all studies. 
The proportion of randomized patients who withdrew 
during treatment were compared between treatments, 
across studies, using a Mantel-Haenszel test stratified for 
the study. A combined relative risk and corresponding 95% 
confidence interval was calculated. The Breslow-Day test 
was used to assess the homogeneity of relative risks between 
studies, and no marked differences between the studies were 
found. The incidence of adverse events occurring in the two 
treatment arms was compared in the same way as the 
withdrawal data. 
Results 
DEMOGRAPHICS 
Of the 19 GlaxoWellcome studies identified, nine met the 
previously defined criteria for inclusion into the meta- 
analysis, and of these, six had been published separately 
(13-l 8). Thus, 1330 patients were available for analysis, 661 
on salmeterol and 669 on theophylline. In the largest study, 
a total of 189 patients were randomized to treatment (13), 
and the smallest study was comprised of 55 patients rand- 
omized to treatment. The details of the studies included in 
the analysis are shown in Table 1. Five of the studies had 
titration periods prior to the treatment period. The effect of 
titration was examined and found not to affect the results of 
this analysis. The studies did not differ markedly in demo- 
graphic details except for study number 9, which entered 
only elderly patients. 
EFFICACY 
No diary card data was available during the run-in for 
study number 4, so this study was excluded from the 
analysis of PEFR because the analysis methods, agreed 
a priori, required this data. 
PEAK EXPIRATORY FLOW RATE 
In the second week of treatment, salmeterol increased the 
mean morning PEFR by 20 1 min - ’ from baseline, while 
theophylline increased the mean morning PEFR by 
10 1 min- ‘. The increase observed with salmeterol was 
significantly greater than that with theophylline (P~O.001). 
Similarly, in the second week, salmeterol increased the 
mean evening PEFR by 16 1 min ~ ’ from baseline, which 
was significantly greater (P<O.Ol) than the mean increase of 
TA
BL
E 
1.
 S
um
m
ar
y 
of
 t
he
 
nin
e 
cli
nic
al 
tri
al
s 
us
ed
 i
n 
th
is 
m
et
a-
an
al
ys
is 
I._
 
,’ 
- 
Pa
tie
nt
s 
St
ud
y 
-ra
nd
om
ize
d 
-- 
, 
,: 
De
sig
n 
Le
ng
th
 
of
 s
tu
dy
 
(w
ee
ks
) 
Tr
ea
tm
en
t 
_ 
Sa
lm
et
er
ol 
Th
eo
ph
yll
ine
 
Th
eo
ph
yll
ine
 
tit
ra
te
d 
W
ith
dr
aw
al
 
M
ea
n 
ag
e 
du
rin
g 
tre
at
m
en
t 
(y
ea
rs
) 
W
) 
(S
D)
 
No
. 
of
 
fe
m
al
es
 
(%
I 
Re
f. 
1 
. 
18
9 
2 
18
5 
3 
17
9 
4 
17
7 
5 
16
0 
6 
14
6 
I 
12
4 
8 
11
5 
9 
55
 
m
c,
 d
b,
 d
d,
 p
g 
m
c,
 o
pe
n,
 p
g 
m
c,
 o
pe
n,
 p
g 
m
c,
 d
b,
 d
d,
 p
g 
m
c,
 d
b,
 d
d,
 p
g 
m
c,
 d
b,
 d
d,
 p
g 
m
c,
 d
b,
 d
d,
 
co
 
m
c,
 d
b,
 d
d,
 
co
 
m
c,
 d
b,
 d
d,
 
pg
 
4 
5O
pg
 
b.
i.d
. 
4 
5O
pg
 
b.
i.d
. 
12
 
50
,u
g 
b.
i.d
. 
16
 
5O
pg
 
b.
i.d
. 
12
 
10
0 
pg
 
b.
i.d
. 
10
 
10
0 
pu
g 
b.
i.d
. 
2 
50
,u
g 
b.
i.d
. 
4 
1O
Op
g 
b.
i.d
. 
4 
5O
pg
 
b.
i.d
. 
2 
15
0 
m
g 
b.
i.d
. 
2 
15
0 
m
g 
b.
i.d
. 
2 
15
0 
m
g 
b.
i.d
. 
10
m
gk
gd
ay
y’ 
2 
15
0 
m
g 
b.
i.d
. 
30
0 
m
g*
 
2 
15
0 
m
g 
b.
i.d
. 
30
0 
m
g*
 
30
0 
m
g 
b.
i.d
. 
Ye
s 
~4
 
we
ek
s 
7 
~5
 
we
ek
s 
22
 
~4
 
we
ek
s 
16
 
No
 
17
 
~4
 
we
ek
s 
18
 
No
 
21
 
14
 
we
ek
s 
8 
No
 
8 
No
 
10
 
44
 (
15
) 
44
 
13
 
42
 (
15
) 
52
 
17
 
50
 (
15
) 
44
 
18
 
43
 (
14
) 
43
 
47
 (
15
) 
46
 
14
 
41
 (
15
) 
47
 
50
 (
14
) 
41
 
15
 
43
 (
13
) 
50
 
16
 
67
 (
4)
 
40
 
*A
lso
 
giv
en
 
ke
to
tif
en
 
1 
m
g 
b.
i.d
. 
co
, 
cr
os
so
ve
r; 
db
, 
do
ub
le-
bli
nd
; 
dd
, 
do
ub
le
-d
um
m
y;
 
m
c,
 m
ul
ti-
ce
nt
re
; 
pg
, 
pa
ra
lle
l 
gr
ou
p.
 
SALMETEROL vs THEOPHYLLINE 259 
2 
$3 
4 
i- 
-20 -10 0 10 20 -20 -10 0 10 20 
Favours theophylline Favours salmeterol Favours theophylline Favours salmeterol 
Mean morning PEFR Mean evening PEFR 
FIG. 1. Overall treatment differences in the change in morning and evening peak flow rate (PEFR) (1 min - ‘) and 95% 
confidence intervals for all nine studies at weeks 2, 3 and 4 in patients receiving theophylline or salmeterol. 
5 1 min ~ ’ observed with theophylline. There was a differ- 
ence between morning and evening PEFR within each 
treatment group, but this was not significantly different 
between the two treatments. Overall treatment differences 
in the improvements in mean morning and evening PEFR 
at weeks 2, 3 and 4 are shown in Fig. 1. It can be seen that 
salmeterol was significantly better than theophylline in 
improving mean morning (WO.002) and evening PEFR 
(WO.02) at each week. 
The treatment differences in mean morning PEFR (and 
95% confidence interval) at week 2 demonstrate some 
variability between individual studies (Fig. 2) but overall 
the mean treatment difference was 10 1 min- ’ in favour of 
salmeterol with a 95’Y” confidence interval from 5 to 
15 1 min - ’ (P<O.OOl). Similarly, the overall treatment dif- 
ference in mean change in evening PEFR at week 2 
significantly favoured salmeterol by 8 1 min- ‘, with a 95% 
confidence interval from 3 to 13 1 min ~ ’ (WO.01). The 
results in the elderly population (study 9) did not appear to 
be different from those in the usual adult population. There 
was no evidence to suggest that the responses to treatment 
differed between titrated and non-titrated studies. 
SYMPTOMS 
The percentage of nights with no symptoms was signifi- 
cantly higher in the salmeterol group at each week; patients 
receiving salmeterol experienced a mean of 63% symptom- 
free nights compared to 52% of nights for patients receiving 
theophylline (WO.001). During week 2, 50% of patients on 
salmeterol had no symptoms on at least 75% of nights 
compared with 38% on theophylline (P<O.OOl) (Fig. 3). 
This treatment difference was maintained at weeks 3 and 4, 
with the proportion of patients with no symptoms on at 
least 75% of nights being 53% for salmeterol and 42% for 
theophylline at week 4 (P<O.OOl). Similarly, salmeterol- 
treated patients had more symptom-free days during weeks 
2-4, with 38% on salmeterol having at least 75% of days 
symptom-free compared with 26% on theophylline at week 
2 (P<O.OOl). Overall, patients receiving salmeterol were free 
from daytime symptoms for a mean of 51% of the days in 
l- I ; w I 
2- - 
3- I I 
study 4- 
5- [ Ir‘-1 
6- I : a w I 
7-l s ;I 
a- l ; a w I 
9- w 
Combined - i W’ 
I I I I 1 I I 
-20 -10 0 10 20 30 40 50 
Favours Favours salmeterol 
theophylline 
FIG. 2. Mean change in morning peak expiratory flow 
rate (PEFR) (1 min ~ ‘) and 95% confidence interval at 
week 2 in each of the nine studies and all of the studies 
combined; *P<O.OOl. Study 4 not included because no 
run-in data was available. 
the second week, compared to 39% for those patients 
receiving theophylline (P<O.OOl). 
The percentage of days when no rescue salbutamol was 
required was significantly higher in the salmeterol group 
(P<O.OOl) at weeks 24, with 36% of patients on salmeterol 
taking no rescue salbutamol on at least 75% of days during 
week 2 compared with 23% on theophylline (Fig. 4). Thus, 
overall, rescue medication with salbutamol was .not 
required on 49% of days for salmeterol-treated patients and 
34% of days for theophylline-treated patients. This treat- 
ment difference was maintained at weeks 3 and 4; the 
percentage of patients requiring no rescue salbutamol on at 
least 75% of days was 38% for salmeterol and 24% for 
theophylline at week 3, and equivalent values were 43 and 
24%, respectively, at week 4. 
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FIG. 3. Distribution of the percentage of symptom-free nights at week 2 in patients receiving either theophylline (0) or 
salmeterol (m). 
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FIG. 4. Distribution of the percentage of rescue-free days (days when rescue medication was not needed) (24 h) at week 2 
in patients receiving either theophylline (0) or salmeterol (M). 
WITHDRAWAL AND ADVERSE EVENTS 
Patient withdrawal rates during the treatment period varied 
between studies (Table 2), but showed a consistent trend 
between treatments, which indicated that, overall, with- 
drawal was significantly more frequent in patients receiving 
theophylline than in those receiving salmeterol (P=O.OOl). 
The odds ratio of withdrawal on salmeterol compared with 
theophylline was 0.65:1, with a 95% confidence interval of 
0.5:1 to 0.85:1. 
Withdrawal due to adverse events during the treatment 
period also varied between studies (Fig. 5), but overall 
significantly more patients on theophylline withdrew due to 
adverse events than those on salmeterol (P=O.O04). Figure 
5 shows the odds ratio and 95% confidence interval for 
each study, and for all studies combined; as ratio values are 
used, by plotting these on a skewed axis, the distance 
of each value from that of 1 (where salmeterol and theo- 
phylline are equivalent) is directly proportional to the 
extent a study favours salmeterol or theophylline. It can be 
seen that for the combined studies, the odds of withdrawal 
due to an adverse event on salmeterol compared with 
theophylline is 0.56:1, with a 95% confidence interval of 
0.38:1 to 0.83:1. 
Incidences of pharmacologically predictable adverse 
events such as asthma, headache, palpitations, tachycardia, 
muscle cramps and tremor were comparable between the 
treatments. Only the reported incidence of gastrointestinal 
disturbances was significantly lower in salmeterol-treated 
patients compared to those receiving theophylline 
(P<O.OOl). The odds of a gastrointestinal event on salm- 
eterol compared with theophylline was 0.31:1, with a 95% 
confidence interval of 0.21:1 to 0.54:1. 
Discussion 
Long-acting inhaled bronchodilators, such as salmeterol, 
have been found to cause bronchodilation that is main- 
tained for at least 12 h, and can be used twice daily in the 
long-term treatment of asthma (3). One of the issues that 
must be addressed when a bronchodilator drug is to be used 
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TABLE 2. Incidence (number of patients with an adverse event/number of patients receiving drug) of 
adverse events during treatment with either salmeterol or theophylline 
Study 
During titration During randomized treatment 
Salmeterol Theophylline Salmeterol Theophylline 
Incidence “/o Incidence % Incidence % Incidence % Ref. 
191208 9 6192 
8/193 4 16196 
151194 8 lo/89 
13187 
531213 25 12174 
1 l/69 
5172 7 12169 17 4167 
3159 
- 4128 
6 8197 8 13 
17 25/89 28 
11 20190 22 
15 18190 20 
16 17/86 20 14 
16 20177 26 
6 7151 12 15 
5 7156 12 16 
14 2127 7 
Study 
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FIG. 5. Odds ratios and 95% confidence intervals for withdrawal as a result of adverse events at week 2 in each of the 
nine studies and for all studies combined. Using a skew distribution allows the distance of each point from 1 to be 
proportional to the extent a study favours salmeterol or therophylline. 
for long-term asthma management is the choice between 
oral theophylline and long acting inhaled &agonists. From 
a therapeutic standpoint, inhaled therapy is preferred 
because of its higher local potency and reduced risk of 
systemic adverse events. However, the relative efficacy of 
the two treatments, patient compliance and possible 
adverse events have to be taken into consideration. 
This meta-analysis provides supportive evidence that in 
symptomatic asthma patients, inhaled salmeterol 50 pg 
twice daily provides better symptom control than a twice 
daily dose (either titrated or non-titrated) of oral theophyl- 
line over a 2- to 4-week treatment period. In comparison 
with theophylline, salmeterol produced a significantly 
greater improvement over baseline in mean morning and 
mean evening PEFR at weeks 24. Furthermore, a signifi- 
cantly higher percentage of patients on salmeterol were 
symptom-free on at least 75% of nights and at least 75% of 
days during this period. Similarly, a significantly higher 
percentage of patients on salmeterol had rescue-free days 
(i.e. did not require salbutamol as rescue medication) on at 
least 75% of days. Salmeterol was better tolerated 
than theophylline, with both the withdrawal rate and the 
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withdrawal rate due to adverse events during treatment 
being significantly greater in the theophylline patients than 
in those on salmeterol. 
Thus, the results of this meta-analysis are in agreement 
with, and add statistical power to, the individual studies 
that have been published (13-18), and also other publi- 
cations comparing inhaled salmeterol50 pg twice daily with 
twice daily oral theophylline in 2- to 4-week randomized, 
controlled studies (e.g. 19-21). 
Theophyllines are difficult drugs to use clinically as there 
is considerable inter- and intra-individual variation in drug 
handling (9). The dose required to obtain a therapeutic 
serum concentration is influenced by a variety of factors, 
including sex, age, diet, cigarette smoking, liver function, 
cardiac failure and concurrent medication (8,9). The recom- 
mended therapeutic range is lo-2Opg ml ~ ‘, but studies in 
general practice (22,23) and hospital practice (24,25) have 
found that theophylline concentrations tend to be sub- 
therapeutic in most patients. Furthermore, attempts at 
dose-titration have not been particularly successful (23,24). 
Thus, if the serum concentrations of theophylline in these 
studies did drop below the minimum therapeutic concen- 
tration (even though in several of the studies, the theophyl- 
line dose was titrated), the clinical effects observed would 
not be optimal, hence increasing the superior efficacy profile 
of salmeterol over theophylline. 
Even allowing the possibility that theophylline and salm- 
eterol have similar efficacy, long-acting &adrenoceptor 
agonists delivered via the inhaled route have distinct safety 
advantages over oral formulations in the management of 
asthma, reducing dose requirements and the incidence of 
adverse events. Moreover, unlike theophyllines, therapeutic 
monitoring is not required. Studies with salmeterol have 
demonstrated that it is well tolerated and highly effective 
when inhaled twice daily in the treatment of asthma. 
In summary, this meta-analysis suggests that salmeterol 
has superior safety and efficacy to theophylline in the 
management of the symptoms of chronic asthma, and 
that salmeterol merits a favourable position relative to 
theophylline in the management of asthma. 
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